Department of Cardiology, the First Hospital of Nanchang, Nanchang, 330006, Jiangxi, China.
Department of Anaesthesia, the People's Hospital of Shangrao, Shangrao, Jiangxi, China.
Nutr J. 2021 Oct 31;20(1):89. doi: 10.1186/s12937-021-00744-y.
The associations between vitamin D and coronavirus disease 2019 (COVID-19) infection and clinical outcomes are controversial. The efficacy of vitamin D supplementation in COVID-19 is also not clear.
We identified relevant cohort studies that assessed the relationship between vitamin D, COVID-19 infection and associated death and randomized controlled trials (RCTs) that reported vitamin D supplementation on the outcomes in patients with COVID-19 by searching the PubMed, EMBASE, and medRxiv databases up to June 5th, 2021. Evidence quality levels and recommendations were assessed using the GRADE system.
Eleven cohort studies with 536,105 patients and two RCTs were identified. Vitamin D deficiency (< 20 ng/ml) or insufficiency (< 30 ng/ml) was not associated with an significant increased risk of COVID-19 infection (OR for < 20 ng/ml: 1.61, 95% CI: 0.92-2.80, I2 = 92%) or in-hospital death (OR for < 20 ng/ml: 2.18, 95% CI: 0.91-5.26, I2 = 72%; OR for < 30 ng/ml: 3.07, 95% CI: 0.64-14.78, I2 = 66%). Each 10 ng/ml increase in serum vitamin D was not associated with a significant decreased risk of COVID-19 infection (OR: 0.92, 95% CI: 0.79-1.08, I2 = 98%) or death (OR: 0.65, 95% CI: 0.40-1.06, I2 = 79%). The overall quality of evidence (GRADE) for COVID-19 infection and associated death was very low. Vitamin D supplements did not significantly decrease death (OR: 0.57, I2 = 64%) or ICU admission (OR: 0.14, I2 = 90%) in patients with COVID-19. The level of evidence as qualified using GRADE was low.
Current evidence suggested that vitamin D deficiency or insufficiency was not significantly linked to susceptibility to COVID-19 infection or its associated death. Vitamin D supplements did not significantly improve clinical outcomes in patients with COVID-19. The overall GRADE evidence quality was low, we suggest that vitamin D supplementation was not recommended for patients with COVID-19.
维生素 D 与 2019 年冠状病毒病(COVID-19)感染和临床结局之间的关联存在争议。维生素 D 补充剂对 COVID-19 的疗效也不清楚。
我们通过检索 PubMed、EMBASE 和 medRxiv 数据库,确定了评估维生素 D 与 COVID-19 感染及相关死亡之间关系的相关队列研究,以及报告 COVID-19 患者中维生素 D 补充对结局影响的随机对照试验(RCT),截至 2021 年 6 月 5 日。使用 GRADE 系统评估证据质量水平和推荐意见。
共确定了 11 项包含 536105 名患者的队列研究和 2 项 RCT。维生素 D 缺乏症(<20ng/ml)或不足症(<30ng/ml)与 COVID-19 感染的风险增加无关(<20ng/ml 的 OR:1.61,95%CI:0.92-2.80,I2=92%)或住院死亡(<20ng/ml 的 OR:2.18,95%CI:0.91-5.26,I2=72%;<30ng/ml 的 OR:3.07,95%CI:0.64-14.78,I2=66%)。血清维生素 D 每增加 10ng/ml 与 COVID-19 感染风险显著降低无关(OR:0.92,95%CI:0.79-1.08,I2=98%)或死亡风险降低无关(OR:0.65,95%CI:0.40-1.06,I2=79%)。COVID-19 感染和相关死亡的总体证据质量(GRADE)非常低。维生素 D 补充剂并未显著降低 COVID-19 患者的死亡率(OR:0.57,I2=64%)或 ICU 入院率(OR:0.14,I2=90%)。使用 GRADE 评估的证据水平为低质量。
目前的证据表明,维生素 D 缺乏或不足与 COVID-19 感染易感性或其相关死亡无关。维生素 D 补充剂并未显著改善 COVID-19 患者的临床结局。总体 GRADE 证据质量较低,我们建议 COVID-19 患者不推荐使用维生素 D 补充剂。